Intuitive Surgical, Inc. (ISRG) — BATS 22/100 — 2026-07-16

Listen to the earnings call audio for free on StockAnalysis

Summary based on Intuitive Surgical, Inc. earnings call on 2026-07-16

BotFlo AI Transformation Score for $ISRG: 22 (22/100)

Sector AI Transformation Score for $ISRG: 10 (10/50)

Presentation

(1/7) Q2 performance and global procedure adoption
• 📈 Total procedures rose 16%, with da Vinci up 15% and Ion up 36%, and the combined installed base neared 13,000 systems.
• 🌍 OUS da Vinci procedure growth was 20%, with Europe and Asia each up 20% and rest of world up 22%.
• ⚠️ U.S. da Vinci growth moderated to 12%, with management citing deferrable procedures and patient coverage or premium dynamics.

(2/7) Capital placements, da Vinci 5 updates, and access platforms
• 🏥 Intuitive placed 468 da Vinci systems and 55 Ion systems, with strong da Vinci 5 adoption including dual consoles.
• 🤖 The first phase of more than 100 planned da Vinci 5 updates targets telepresence, simulation-based training, and Care Team workflow.
• 💰 XiR adoption increased in cost-constrained OUS markets and U.S. ambulatory surgery centers to expand access.

(3/7) Extended use instruments, SP, Ion, and early R&D
• 🔧 An extended use program expected in the first half of 2027 will increase uses on a subset of EndoWrist instruments to lower cost in benign procedures.
• 📈 SP procedures grew 61% with 38 SP placements, and Ion procedures rose 36% to 48,000 with cumulative volume above 400,000.
• 🔬 Intuitive submitted a foundational noncommercial next-generation flexible robotic endoscope for GI tract use for FDA 510(k) clearance.

(4/7) Strategy, AI and ML investment, and value positioning
• 🎯 Innovations are designed to advance clinical outcomes, patient and provider experience, access, and affordability across complex and high-volume procedures.
• 🤖 Sustained investment spans artificial intelligence and machine learning, robotics, instrumentation, imaging, and advanced materials.
• 🏭 Management plans to keep investing, including increasing R&D, to differentiate solutions, improve durability, and reduce total cost of care.

(5/7) Financial results and My Intuitive+ AI insights
• 💵 Revenue rose 19% to $2.89 billion, non-GAAP operating margin was 42%, and non-GAAP EPS increased 28%.
• 📊 Recurring revenue was 85% of total, utilization rose 3% for da Vinci and 11% for Ion, and systems revenue grew 19% to $685 million.
• 🤖 First-wave My Intuitive+ renewals for telepresence, simulation, and AI-driven case insights saw no customer opt-outs.

(6/7) Clinical evidence highlights
• 📉 A multi-hospital appendectomy study associated robotic assistance with 0% conversion to open versus 3.2% for laparoscopy and a 66% lower adjusted complication risk.
• 🩺 Authors linked better robotic appendectomy results to 3D visualization and wristed-instrument dexterity.
• ⏱️ A Force Feedback nephrectomy cohort showed 63% return of bowel function within one day versus 28% without Force Feedback.

(7/7) Updated 2026 financial outlook
• 📈 Full-year 2026 da Vinci procedure growth guidance is maintained at 13.5% to 15.5%, expected near the midpoint.
• 💰 Non-GAAP gross margin outlook was raised to 68% to 69% of revenue after tariff assumptions changed.
• 🧾 Non-GAAP operating expense growth is now expected at 11% to 13%, with R&D continuing to outpace SG&A.

Q&A

(1/14) Q&A: How much U.S. procedure moderation is ACA versus market maturity, and will delayed cases return?
• 🗣️ Jamie said the view rests on customer feedback plus weaker trends in deferrable procedure types versus less deferrable cases.
• 📊 U.S. da Vinci procedure growth was 12% in Q2 versus 14% in Q1.
• ⚠️ Management sees a likely mix of ACA impact and law-of-large-numbers effects.

(2/14) Q&A: Framework for extended-use I&A impact and ASC or international expansion
• ⏳ Jamie declined to quantify extended-use impact yet and said quantification would come on the next earnings call.
• 💰 Life-extension improvements are intended to lower cost in benign outpatient procedures and lower-reimbursement geographies.
• 📈 Impact in 2027 is expected to be progressive by country rollout rather than a step function, informed by the 2020 extended-use experience.

(3/14) Q&A: U.S. and OUS capital environment and CapEx assumptions
• 🏥 Jamie described the U.S. capital environment as stable, with Q2 U.S. placements up 24% and a still-healthy pipeline.
• 💳 About 70% of U.S. systems are leased, giving customers flexibility under budget constraints, with demand driven by da Vinci 5.
• 🌍 Internationally, China remains competitive and price-challenged, Japan shows cautious optimism after June reimbursement changes, and Europe is mixed by market.

(4/14) Q&A: Cadence and impact of more than 100 da Vinci 5 upgrades
• ⚙️ Dave said da Vinci 5’s compute power enables regular capability adds, with the referenced release covering about 100 updates.
• 🛠️ Three submitted 510(k) items include tool-inject communication, multi-arm adjustment for efficiency, and a digital ruler for anatomic measurement.
• 🚀 Future years are expected to bring additional standout features that improve system capability, usability, and efficiency.

(5/14) Q&A: Why a GI robot now and what is the opportunity size?
• 🎯 Dave framed GI as a natural extension of bringing better minimally invasive care to more patients, building on da Vinci and Ion learnings.
• 🩺 Work with GI physicians targets therapeutic outcomes and care-team experience under the Quintuple Aim.
• ⚠️ The 510(k) is for a noncommercial endoluminal system and management is not ready to size timing or TAM.

(6/14) Q&A: Is surgical robotics in China’s centralized VBP and what is the impact?
• 🇨🇳 Dave said the tender centralization should not necessarily be compared with VBP.
• 📋 The government appears focused on reducing duplication and waste in hospital- and province-level tenders.
• 🤖 Robotics is expected to be included, with more structured tenders reinforcing strong robotic programs over bespoke feature checklists.

(7/14) Q&A: Tangible benefit of enhanced instrument encryption and security
• 🔒 Dave said cybersecurity is front and center for customers globally.
• 🛡️ New encryption technology is part of continued investment to strengthen product security, quality, and availability.
• 📌 Management centered the discussion on strengthening products rather than quantifying hospital switching incentives versus remanufactured instruments.

(8/14) Q&A: Does strong capital demand imply rising future procedure demand?
• 🔄 About half of U.S. Q2 placements were trade-ins, so much capital activity upgrades capacity without fully expanding the installed base.
• 📊 U.S. system utilization grew a healthy 3% in Q2 and remains a watched metric.
• 👀 Some customers express ACA enrollment caution, but it has not affected the capital pipeline so far.

(9/14) Q&A: What inning is the da Vinci 5 upgrade cycle in?
• 📚 Jamie cited the Si-to-Xi transition, which took about seven years to reach peak trade-in volumes, as historical context only.
• 🛠️ da Vinci 5 attractiveness should increase over time as software updates and ecosystem elements improve.
• ⏳ Management continues to view the upgrade cycle as progressive over multiple years, with segmentation across hospitals, HOPDs, and ASCs.

(10/14) Q&A: XiR placement momentum and future mix
• 🎯 Dave said XiR fits ASCs, smaller hospitals, and cost-constrained geographies while leveraging the full Gen 4 ecosystem.
• 📈 Management expects XiR to be a significant part of placements over coming quarters.
• 🌐 Jamie estimated roughly 130 XiRs installed after about a year, including about 50 in the U.S. and uptake across 11 or 12 countries.

(11/14) Q&A: How significant could Japan reimbursement changes be over time?
• 🇯🇵 Procedure adoption is expected to take time due to newer categories and surgeon training needs.
• ⚖️ Management remains balanced about ongoing financial challenges alongside new incentives, expecting progressive uptake.
• 🩺 Inguinal hernia is the largest newly reimbursed procedure opportunity, and incremental TAM was not specifically quantified on the call.

(12/14) Q&A: Will extended use flatten or reduce I&A per case in 2027–2028?
• 🚫 Jamie again declined to quantify 2027 I&A impact until internal analysis and pricing decisions are complete.
• 📈 Intuitive balances growth and profitability and will pursue lower-acuity growth where incremental opportunity exists.
• Mixed Mix tailwinds from innovative higher-priced products can offset extended-use pressure, as described in prepared remarks.

(13/14) Q&A: Procedure exposure to Medicaid and health-care exchanges
• 💳 Jamie said Intuitive lacks a precise estimate of ACA exchange exposure.
• 📊 A significant portion of the business is private or commercial insurance.
• 📉 Medicare is a lower share and Medicaid is lower still.

(14/14) Q&A: Do tougher third-quarter comps matter for the back-half guide?
• 📅 First-half da Vinci procedure growth was closer to 15%, while the full-year guide centers nearer the midpoint.
• 🇺🇸 There is a somewhat tougher U.S. comp in Q3.
• 🌍 International Q3 and Q4 are also affected by last year’s seasonal holiday shift from Q4 into Q3.